Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Biomea Fusion, Inc. (BMEA)
A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Biomea Fusion, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.98HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
BMEA
Biomea Fusion, Inc.
$1.27HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Total return — ACRV vs BMEA
growth of $100 · dividends reinvested · last 4yACRV -88.1% (-41.3%/yr)BMEA -83.7% (-36.4%/yr)BMEA compounded faster over this window
ACRV BMEA
ACRV vs BMEA: by the numbers
- •BMEA is the larger company ($92M vs $85M market cap).
Metrics side by side
Valuation
| Metric | ACRV | BMEA |
|---|---|---|
| P/B ratio | 0.98 | 7.57 |
Profitability
| Metric | ACRV | BMEA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -85.65% | -268.09% |
| ROIC | -88.28% | -220.02% |
Growth (annualized)
| Metric | ACRV | BMEA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -36.56% |
Go deeper
Dig into the metrics
Acrivon Therapeutics, Inc. Common Stock ROEBiomea Fusion ROEAcrivon Therapeutics, Inc. Common Stock operating marginBiomea Fusion operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthBiomea Fusion revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowBiomea Fusion free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.